| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 109.45 | 1.0% | 64.4% |
| Total Income | 109.45 | 1.0% | 64.4% |
| Expenditure | 103.95 | 14.8% | 52.4% |
| PBT | 7.52 | 59.4% | 3369.6% |
| Net Profit | 8.05 | 55.2% | 3320.0% |
| OPM | 5.03% | 11.43pp | 7.47pp |
| NPM | 7.36% | 9.22pp | 7.73pp |
| EPS | 0.17 | 56.4% | 950.0% |
BillionToOne Reports Q2 2026 Results, Revenue Up 64% to $109.4 Million
06 Aug 2026 · 6 Aug, 2:02 am
Summary
BillionToOne reported strong second quarter 2026 financial results, with total revenue increasing 64% year-over-year to $109.4 million, driven by robust growth in both prenatal and oncology testing segments. The company also achieved a significant improvement in gross profit margin to 70% and returned to profitability with an income from operations of $5.5 million. BillionToOne reiterated its full-year 2026 revenue guidance and expects to maintain current profitability levels despite continued investments.
Key Highlights
- 1
Total revenue reached $109.4 million in the second quarter of 2026, marking a significant 64% increase compared to $66.6 million in the second quarter of 2025.
- 2
Prenatal clinical testing revenue grew by 55% year-over-year to $94.2 million in Q2 2026.
- 3
Oncology clinical testing revenue saw substantial growth, increasing 176% to $13.7 million in Q2 2026 from $4.9 million in Q2 2025.
- 4
Gross profit margin improved to 70% in the second quarter of 2026, a 5 percentage-point increase from 65% in the prior year's second quarter.
- 5
The company delivered 196,000 tests in Q2 2026, up 35% from 145,000 tests in Q2 2025.
- 6
Income from operations was $5.5 million in Q2 2026, a significant improvement from a $1.6 million operating loss in Q2 2025.
- 7
BillionToOne reiterated its full-year 2026 revenue guidance in the range of $450 million to $465 million, representing 48% to 52% growth over 2025.
Management Comments
Dr. Oguzhan Atay
Our second quarter demonstrated the durability of our model, with our differentiated technology platform, category-defining products, and disciplined execution driving continued growth and profitability. We grew revenue 64% year-over-year to a $438 million annualized run-rate while advancing our product roadmap with the launch of Unity Confirm and the upcoming launches of our expanded Fetal Risk Screen and Northstar Origin. We believe we are still in the earliest chapters of what our smNGS platform can achieve, and we remain relentlessly focused on transforming molecular diagnostics and healthcare.
Informational and educational content only. Not investment advice.